Carlos Camps Herrero-rekin lankidetzan egindako argitalpenak (4)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

2018

  1. Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii490

  2. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536